(SDGR) Schrodinger - Ratings and Ratios

Schrödinger, Inc. (NASDAQ:SDGR) is a leading developer of physics-based computational platforms designed to accelerate the discovery of novel molecules for pharmaceuticals and materials science. The company operates through two primary segments: Software and Drug Discovery. The Software segment provides advanced molecular modeling solutions to the life sciences and materials industries, enabling researchers to optimize and accelerate discovery workflows. The Drug Discovery segment focuses on developing a pipeline of preclinical and clinical candidates, both independently and through strategic collaborations.

Schrödinger has established a notable research collaboration and license agreement with Novartis Pharma AG, aimed at advancing multiple development candidates across various therapeutic areas. This partnership underscores the companys commitment to leveraging its computational capabilities to address complex challenges in drug discovery. Incorporated in 1990 and headquartered in New York, New York, Schrödinger has become a key player in the intersection of technology and life sciences. For more information, visit their website at https://www.schrodinger.com.

### 3-Month Forecast: - Price Target: $28.50 - Technical Outlook: - The stock is trading above its 20, 50, and 200-day SMAs, indicating bullish momentum. - Support levels are likely to hold around $22.50 (SMA 50). - Resistance is anticipated at $28.00. - Volatility: - Average True Range (ATR) of 1.62 suggests moderate price fluctuations. - Fundamental Outlook: - High P/S ratio (9.24) reflects strong revenue growth expectations. - Negative RoE (-44.40) indicates ongoing investments in growth initiatives. - Market cap of $1.917B underscores its position as a mid-sized growth company in the Health Care Technology sector.